1. A Clinical Trial To Evaluate The Safety And Efficacy Of Saroglitazar Compared To Fenofibrate In Patients With Dyslipidemia. (August 2019) Authors: Parmar, D.; Krishnappa, M.; Arifahmed, F.; Mali, N.; Patel, J.; Shah, M.; Parmar, K.; Shah, C.; Faldu, K. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. In silico toxicity prediction using Derek Nexus® for skin sensitization, phototoxicity, hepatotoxicity and in vitro hERG inhibition. (September 2021) Authors: Ahuja, V.; Krishnappa, M.; Kandarova, H. Journal: Toxicology letters Issue: Volume 350(2021)Supplement Page Start: S250 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LP-07 In silico analysis using Derek and Sarah along with ICH M7 expert review accurately predicts Mutagenicity and Carcinogenicity of Nitrosamines. (1st September 2022) Authors: Ahuja, V.; Krishnappa, M. Journal: Toxicology letters Issue: Volume 368(2022)supplement 1 Page Start: S286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases. (August 2019) Authors: Krishnappa, M.; Shah, M.; Parmar, K.; Joshi, S.; Maroo, S.; Parmar, D. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗